Edwards End Period Cash Flow from 2010 to 2024

EW Stock  USD 69.38  0.97  1.38%   
Edwards Lifesciences End Period Cash Flow yearly trend continues to be fairly stable with very little volatility. End Period Cash Flow is likely to outpace its year average in 2024. During the period from 2010 to 2024, Edwards Lifesciences End Period Cash Flow regression line of quarterly data had mean square error of 35779.9 T and geometric mean of  568,591,823. View All Fundamentals
 
End Period Cash Flow  
First Reported
2000-03-31
Previous Quarter
1.2 B
Current Value
1.6 B
Quarterly Volatility
436.9 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Edwards Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Edwards Lifesciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 89.7 M, Interest Expense of 10.6 M or Selling General Administrative of 1.8 B, as well as many indicators such as Price To Sales Ratio of 4.36, Dividend Yield of 0.0 or PTB Ratio of 4.82. Edwards financial statements analysis is a perfect complement when working with Edwards Lifesciences Valuation or Volatility modules.
  
Check out the analysis of Edwards Lifesciences Correlation against competitors.

Latest Edwards Lifesciences' End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of Edwards Lifesciences Corp over the last few years. It is Edwards Lifesciences' End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Edwards Lifesciences' overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Slightly volatile
   End Period Cash Flow   
       Timeline  

Edwards End Period Cash Flow Regression Statistics

Arithmetic Mean742,526,667
Geometric Mean568,591,823
Coefficient Of Variation50.55
Mean Deviation290,784,889
Median772,600,000
Standard Deviation375,350,968
Sample Variance140888.3T
Range1.2B
R-Value0.87
Mean Square Error35779.9T
R-Squared0.76
Significance0.00002
Slope73,370,357
Total Sum of Squares1972436.9T

Edwards End Period Cash Flow History

20241.2 B
20231.1 B
2022772.6 M
2021867.4 M
20201.2 B
20191.2 B
2018714.1 M

About Edwards Lifesciences Financial Statements

Edwards Lifesciences investors use historical fundamental indicators, such as Edwards Lifesciences' End Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Edwards Lifesciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
End Period Cash Flow1.1 B1.2 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Edwards Stock Analysis

When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.